Indian children aged 12 or older will become eligible for COVID-19 vaccinations from next month, when Indian pharmaceutical company Cadila Healthcare (NSE:CADILAHC) launches its ZyCoV-D product, Reuters news agency reported on Wednesday, citing two sources with direct knowledge of the matter.
ZyCoV-D , the world's first DNA-based COVID-19 vaccine, won emergency authorisation from Indian regulators last month.
From October 2021, the company, better known as Zydus Cadila, is expected to produce 10 million doses a month.
This COVID-19 vaccine is the only one approved for children in India, Reuters added.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma